Please login to the form below

Not currently logged in

Arena transfers US marketing rights for Belviq to Eisai

Japanese pharma firm Eisai will also handle marketing applications in North and South America

Eisai has received US marketing rights to the weight loss drug Belviq (lorcaserin) from its development partner Arena Pharmaceuticals, and will now be responsible for commercialisation of the drug in the country.

Belviq was approved by the Food and Drug Administration (FDA) in June, 2012, as the first new drug available to treat obesity in the US in 13 years, with Arena the company to initially submit its New Drug Application (NDA).

Eisai will now take over all pharmacovigilance requirements related to the drug, which includes a comprehensive post-marketing surveillance commitment to study Belviq's long-term safety.

In addition, Eisai plans to submit marketing authorisation applications based on the US NDA to health authorities throughout the Americas for which it currently holds commercialisation rights, including Mexico, Brazil and Canada.

The drug is approved in the US for adults who are classified as obese or overweight with at least one medical complication such as diabetes or high cholesterol.

It works through activating the 5-HT2C brain, leading to patients feeling fuller on a smaller amount of food, and is to be used in conjunction with a reduced calorie diet and increased exercise.

Further competition in the US is expected soon, with Vivus announcing it is planning to launch its rival weight-loss treatment Qsymia (formerly known as Qnexa) during the fourth quarter of 2012 following approval from the FDA.

1st August 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

White paper download: Creating experiences to improve patient outcomes
Download our white paper "Creating experiences to improve patient outcomes" to learn the steps to building an effective customer experience strategy....
Organisational Memory
In a knowledge-based industry with high labour mobility, retaining that knowledge within an organisation during a drug’s lifecycle can be tricky. If we undervalue the knowledge, experience and marketing understanding...
Thoughts on the intersection between technology and psychology
Paul Mannu - Master Practitioner, Behavioural Insights at Cello Health Insight gives us his succinct thoughts on the intersection between technology and psychology...